Abstract 245P
Background
Currently, the ambiguous role of neutrophils (Nph) in renal cancer (RC), which is determined by their phenotype, is of considerable interest. TGF-β is able to change the expression of pro-inflammatory cytokines of Nph and their receptors, as well as stimulate the production of chemokines that attract Nph to the site of inflammation, thus forming a pro-tumor phenotype (N2). TGF-β in the tumor microenvironment induces the migration of the CD11b+ Nph population. CD11b provides adhesion, migration, degranulation of Nph. Therefore, the study was aimed at assessing the expression of the TGF-β gene, as well as CD11b receptors, by circulating Nph at different stages of RC.
Methods
The study included patients with stage I-II (n=20), stage III-IV (n=20) clear cell RC (Med 62 years) and 20 - control group (CG) (Med 60 years). The study was approved by the Ethics Committee of the IME&PС of UlSU (prot. No. 1, 01/15/2020). RNA was isolated from the fraction of peripheral blood Nph on SileksMagNA magnetic particles (Sileks, Russia). After isolation, a reverse transcription reaction was performed. Expression of the TGF-β gene was determined by quantitative reverse transcription PCR using primers (Evrogen, Russia). Immunophenotyping was performed using monoclonal antibodies to the surface antigen CD11b (Sorbent, Russia). The results were expressed as Med (Q1-Q3). Statistical processing was performed using the Statistica 13, using the Mann–Whitney U-test and the Spearman correlation coefficient (p<0.05).
Results
A significant increase in the expression of the TGF-β gene in Nph was found in patients with RC compared with the CG (0.07 (0.12-2.21) vs 0.05 (0.04-0.13), p=0, 008), and also depending on the stage: at I-II stages of RC 0.43 (0.09-1.21), at III-IV 1.91 (0.87-3.18) (p=0.05). A significant increase in the expression of CD11b on the surface of Nph was found in patients with RC 73.3±5.1% vs the CG 19.0±9.3% (p=0.001), while no relationship with the stage was found. A direct correlation was found between TGF-β and CD11b gene expression in Nph (r=0.48, p=0.01).
Conclusions
In RC, the affinity of circulating neutrophils to the tumor microenvironment increases. At the same time, the level of expression of the growth factor TGF-β increases in Nph.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract